934524-10-4

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyriMidine is used as a building block for the synthesis of pharmaceuticals due to its unique structure and reactivity. Its potential applications in drug development make it a valuable compound for further investigation in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical industry, 2,4-Dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyriMidine is used as a building block for the synthesis of agrochemicals. Its unique properties and reactivity contribute to the development of new and effective agrochemical products.
Used in Organic Synthesis:
2,4-Dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyriMidine is used as an intermediate in organic synthesis due to its unique structure and reactivity. Its properties make it a valuable compound for the development of new organic compounds and materials.

InChI:InChI=1/C13H9Cl2N3O2S/c1-8-2-4-9(5-3-8)21(19,20)18-7-6-10-11(14)16-13(15)17-12(10)18/h2-7H,1H3

Upstream product

• 90213-66-4 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 
• 98-59-9 p-toluenesulfonyl chloride 
• 63200-54-4 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 
• 39929-79-8 7-deazaxanthine 
• 7355-55-7 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 
• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 104-15-4 toluene-4-sulfonic acid 
• 934524-13-7 4-chloro-7-[(4-methylbenzene)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-2-amine 

Downstream Products

• 1086610-84-5 7-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-2,3-dihydro-1H-isoindol-1-one 
• 1086611-08-6 2-bromo-6-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzoic acid 
• 1086611-05-3 2-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzoic acid 
• 1086610-82-3 2-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzamide 
• 1122710-25-1 N-(2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzolthiazol-5-amine 
• 1122709-91-4 2-chloro-N-(3-methyl-1H-indazol-6-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1122709-87-8 2-chloro-N-(1H-indazol-6-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1122709-96-9 N-(1H-benzo[d]imidazol-6-yl)-2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1122710-44-4 2-chloro-N-(1H-indazol-4-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1122710-35-3 2-chloro-N-(1-methyl-1H-indazol-6-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1122710-39-7 2-chloro-N-(1-methyl-1H-indazol-5-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1147014-58-1 2-chloro-4-((2-isopropylphenyl)ethynyl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine 
• 1372263-39-2 N-(2-(((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)methyl)phenyl)-N-methylmethanesulfonamide 
• 1616474-11-3 2-chloro-4-(3-(pyridin-3-ylmethoxy)phenyl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to heteroaromatic derivatives for use as a regulator, a preparation method therefor and a use thereof. In particular, disclosed are compounds represented by general formula (I), preparation methods therefor, pharmaceutical co

Pyrrolopyrimidine BTK inhibitor as well as preparation method and application thereof

The invention provides a pyrrolopyrimidine BTK inhibitor as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The compound has the structural general formula shown in a formula (I). In-flight

NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT

The present invention relates to a novel fused pyrimidine based sulfonamide derivative represented by Formula I, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient. The novel fused pyrimidine based sulfonamide derivative of the present invention can effectively suppress the growth of cancer cells and resistance to drugs, which are induced by mutations in the tyrosine kinase domain of epidermal growth factor receptors, or the growth of cancer cells having such resistance.

Pyrrolopyrimidine derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and provides a compound shown as a general formula (I), geometric isomers or pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and preparation methods thereof, wherein A, B and R1 are described in the claims and the specification. The compound and the geometric isomer thereof or the pharmaceutically acceptable salt, hydrate, solvate, prodrug or pharmaceutical composition thereof have the activity as a protein kinase inhibitor, especially an FAK kinase inhibitor.

Pyrrolopyrimidine derivatives used as protein kinase inhibitors and application thereof

The invention discloses pyrrolopyrimidine derivatives as protein kinase inhibitors and application thereof, and geometric isomers or pharmaceutically acceptable salts, hydrates, solvates or prodrugs of the pyrrolopyrimidine derivatives. In-vivo and in-vit

Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study

Focal adhesion kinase (FAK) is an intracellular non-receptor tyrosine kinase responsible for development of various tumor types. Aiming to explore new potent inhibitors, two series of 2,4-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives were designed and synthesized on the base of structure-based design strategy. Biological evaluation indicated that most of these new compounds could potently inhibit FAK kinase, leading to the promising inhibitors against the proliferation of U-87MG, A-549, and MDA-MB-231 cancer cell lines. Among them, the optimized compound 18h potently inhibited the enzyme (IC50 = 19.1 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.35, 0.24, and 0.34 μM, respectively. Compound 18h is a multi-target kinase inhibitor. Furthermore, compound 18h also exhibited relatively less cytotoxicity (IC50 = 3.72 μM) toward a normal human cell line, HK2. According to the flow cytometry and wound healing assay results, compound 18h effectively induced apoptosis and G0/G1 phase arrest of MDA-MB-231 cells and suppressed the migration of U-87MG, A-549 and MDA-MB-231 cells. The docking study of compound 18h was performed to elucidate its possible binding modes and to provide a structural basis for the further structural guidance design of FAK inhibitors. Collectively, these data support the further development of compound 18h as a lead compound for FAK-targeted anticancer drug discovery.

2,4-DIAMINOPYRIMIDINE BICYCLES FOR TREATING CANCER

A genus of quinazoline and pyrrolo[3,2-d]pyrimidine derivatives is disclosed. The compounds are of the genus (I). The compounds selectively inhibit subfamilies of AAA+ proteins and TrkA-C. They are useful in the treatment of Alzheimer's disease and as anticancer agents.

Aryl phosphorus oxides for restraining kinase activity

The invention relates to aryl phosphorus oxides having a restraining effect on protein tyrosine kinase, a drug combination including the aryl phosphorus oxides, and preparation and purpose of the arylphosphorus oxides, and particularly discloses a compoun

Substituted diaminopyrimidine compound

The present invention provides a substituted diaminopyrimidine compound represented by a formula (I), or a pharmaceutically acceptable salt, a crystal form, a prodrug, a metabolite, a hydrate, a solvate, a stereoisomer or an isotope derivative thereof, as well as a pharmaceutical composition and uses thereof. The compound provided by the invention can be used for treating ALK-mediated related diseases, such as non-small cell lung cancer, breast cancer, neural tumor, esophageal cancer, soft tissue cancer, lymphoma and leukemia.

Structure-Based Design of Selective, Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors

The ability of G protein-coupled receptor (GPCR) kinases (GRKs) to regulate desensitization of GPCRs has made GRK2 and GRK5 attractive targets for treating heart failure and other diseases such as cancer. Although advances have been made toward developing inhibitors that are selective for GRK2, there have been far fewer reports of GRK5 selective compounds. Herein, we describe the development of GRK5 subfamily selective inhibitors, 5 and 16d that covalently interact with a nonconserved cysteine (Cys474) unique to this subfamily. Compounds 5 and 16d feature a highly amenable pyrrolopyrimidine scaffold that affords high nanomolar to low micromolar activity that can be easily modified with Michael acceptors with various reactivities and geometries. Our work thereby establishes a new pathway toward further development of subfamily selective GRK inhibitors and establishes Cys474 as a new and useful covalent handle in GRK5 drug discovery.